Literature DB >> 35314462

Telemedicine in post-molar follow-up: is it a useful tool?

Rafaela Tessaro de Assis1, Luiza Russo de Morais2, Ana Carolina Ferreira Simões de Freitas1, Roney Cesar Signorini FIlho1, Lucas Ribeiro Borges de Carvalho1, Bruna Elias Parreira1, Cíntia Yurie Yamachi3, Antonio Braga4, Sue Yazaki Sun1.   

Abstract

BACKGROUND: Telemonitoring is an alternative to in-person appointments and overcomes geographic distance barriers.
OBJECTIVE: The primary objective of this study was to evaluate adherence to post-molar follow-up using both WhatsApp and in-person appointments compared with standard care. The secondary objective was to evaluate the rate of completion of post-molar follow-up of complete moles, considering 6 and 3 months of duration.
METHODS: This retrospective cohort study was conducted at the Gestational Trophoblastic Disease Center, São Paulo Hospital. Patients with complete or partial mole treatment between January 1, 2009 and December 31, 2018 were included in two groups: group 1 (patients from 2009 to 2013) and group 2 (from 2014 to 2018), before and after telemonitoring implementation, respectively. Complete follow-up was considered if after the first normal human chorionic gonadotropin (hCG) level (<5 mIU/mL), the patient was followed up for an additional 30 days (partial mole) or 180 days (complete mole). Loss to post-molar follow-up with positive hCG was also evaluated. Statistical analysis was performed using Pearson's Χ2 test, 5% significance level (p=0.05), and R version 4.0.2.
RESULTS: A total of 308 patients were included in the study, 92 of them were assessed in group 1 and 216 patients in group 2. There was no difference between the rates of complete follow-up after telemonitoring implementation (complete mole: 42/72=58.3% group 1 vs 85/163=52.1% group 2; p=0.38; partial mole: 16/20=80% group 1 vs 37/53=69.8 group 2; p=0.3), and no increase of loss to post-molar follow-up with positive hCG (8/92=8.7% group 1 vs 14/216=6.5% group 2; p=0.49). The shortening of follow-up of complete moles to 90 days increased the rate of complete post-molar follow-up (from 127/235=54.0% to 189/235=80.4%, p<0.001).
CONCLUSIONS: The association of telemonitoring with in-person appointments could have had an advantage in post-molar follow-up since it did not reduce adherence to hormonal surveillance. Shortening post-molar follow-up after complete mole to 90 days after the first normal hCG level increased the rate of complete post-molar follow-up. © IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  Gestational Trophoblastic Disease; Hydatidiform Mole; Pregnancy Complications, Neoplastic; Trophoblastic Neoplasms

Mesh:

Substances:

Year:  2022        PMID: 35314462     DOI: 10.1136/ijgc-2021-003260

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  1 in total

1.  Development and validation of a health information system for assistance and research in gestational trophoblast disease.

Authors:  Jaqueline Martins; Paulo Bandiera-Paiva; Antonio Rodrigues Braga Neto; Lucas Ribeiro Borges de Carvalho; Lúcio Padrini-Andrade; Vitor Tonini Machado; Antônio Carlos da Silva Junior; Sue Yazaki Sun
Journal:  BMC Med Inform Decis Mak       Date:  2022-07-01       Impact factor: 3.298

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.